USA flag logo/image

An Official Website of the United States Government

A Real-Time, Label-Free Diagnostic Platform with Glycan Arrays

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85981
Program Year/Program:
2007 / SBIR
Agency Tracking Number:
RR024293
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
AlphaSniffer LLC
1745 38th Street, Suite A Boulder, CO 80301 2505
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2007
Title: A Real-Time, Label-Free Diagnostic Platform with Glycan Arrays
Agency: HHS
Contract: 1R43RR024293-01
Award Amount: $200,000.00
 

Abstract:

DESCRIPTION (provided by applicant): The ultimate goal of the proposed work is to develop a compact, label free, sensitive and real-time platform capable of multiplex detection of biomarkers and pathogens using glycan microarrays. Glycans, which are predom inant surface components of immune cells and microorganisms, give rise to high levels of anti-glycan antibodies of all classes that can be used for diagnosis and prognosis. During Phase I of this project, AlphaSniffer will develop glycan microarrays for th e detection of two plant lectins, Concanavalin A and jacalin as model analytes to investigate the feasibility of incorporating glycomic tools into its optical platform for multiplex detection. Our long-term vision is to develop a system comprising an instr ument and application-specific disposable cartridges that are capable of rapid detection of multiple target pathogens and biomarkers. This system will provide significant advantages over current test methods that take many hours to several days to provide results, and typically only yield information about single pathogens. As an analytical instrument company, AlphaSniffer realized the market's need of a label-free, real-time, robust and sensitive diagnostic platform and is developing the Surface Plasmon Re sonance-enhanced Common Path Interferometry platform especially for this purpose. Phase I project will pursue the following objectives: 1. Design and prepare mono- and disaccharide substituted polymeric transducers; 2. Optimize binding density, multi-valen cy and mitigate nonspecific binding; 3. Implement binding assays for concanavalin A (ConA) and jacalin as model sugar binding proteins; 4. Test the four spot prototype system and generate binding concentration-response curves. The results of this investiga tion will establish the feasibility of incorporating glycan microarrays into AlphaSniffer's platform and will enable the Phase II research and development to design and develop glycan immobilized transducers for diagnostic and prognostic purposes. G reat achievements have been made in understanding the genetic code of disease. However the next great opportunities for influencing public health demand understanding the function of the cellular machinery created by our DNA's instructions. In order to ach ieve this goal, it is imperative that technologies such as AlphaSniffer's SPR-CPI platform be developed that can analyze the cellular functions of protein and carbohydrates in their natural state, without the use of labels that often change the way these b iomolecules behave. The research proposed here seeks to expand the toolbox applied in analysis of cellular carbohydrates and establish processes to further biochemical understanding of their more subtle purposes. The results of this research will be practi cally applied to protect public health and enhance medical treatment.

Principal Investigator:

Bilge Hacioglu
3035455550
BILGEHACIOGLU@COMCAST.NET

Business Contact:

Mikhail Plam
chad@bioptix.com
Small Business Information at Submission:

ALPHASNIFFER, LLC
BiOptix, LLC 1745 38th ST, STE A BOULDER, CO 80301

EIN/Tax ID: 200074431
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No